Exact Imaging

  • Start-ups & scale-ups
  • Life Sciences & Care
  • Portfolio Life Sciences & Care
  • Life sciences & care

Micro-ultrasonic imaging for improved prostate cancer treatment

Exact Imaging is the world leader in high-resolution micro-ultrasonic systems that enable real-time imaging and guided biopsies in the urological prostate cancer market. Exact Imaging’s 29 MHz ExactVu™ micro ultrasound platform enables a whole new level of resolution with great ease of use and affordability, and is an extension of the current urological workflow.

Using the Exact Imaging platform, urologists can visualise specific areas in the prostate and perform region-specific biopsies. For those cases where MRI could help (i.e. previous negative biopsies), the FusionVu™ micro-US/MRI fusion application operates on the ExactVu micro-echography platform and enables MRI fusion-based targeting.

The ExactVu micro-echography system, including the FusionVu application, is legally approved in the European Union (CE marking), the United States (FDA 510(k)) and Canada (Health Canada medical device licence).

Partners in ambition with Exact Imaging

Exact Imaging raises $16.3m (CDN $21.5) in a Series C round for the commercialisation of its ExactVu™ micro-ultrasound system. The financing, finalised in late 2016, is led by Lumira capital (Toronto, ON) and Vesalius Biocapital (Luxembourg) with participation from additional investors such as PMV (Brussels, Belgium) and existing investors iGan Partners/Rowanwood Ventures (Toronto, ON).